Advertisement
Screener

VIATRIS INC. (VTRS) EBITDA

VIATRIS INC. (VTRS) EBITDA

  • 2026-06-30: Basis Reported; EBITDA $678.6M; Operating income (m); Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA $596.4M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA $574.1M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA $867.3M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2018-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported$678.6M(m)(m)$3.75B18.12%$52.80M*$381.80M*$2.30B$248.30M$1.13B$54.80M
2026-03-31Reported$596.4M(m)(m)$3.51B16.99%$39.90M$388.30M$2.36B$248.60M$928.80M-$423.70M
2025-12-31Reported$574.1M(m)(m)$3.69B15.56%(m)(m)(m)(m)(m)(m)
2025-09-30Reported$867.3M(m)(m)$3.75B23.14%$86.80M*$744.90M*$2.39B$250.40M$886.60M$120.30M
2025-06-30Reported$911.3M(m)(m)$3.57B25.53%$52.90M*$219.70M*$2.25B$218.80M$928.70M-$212.50M
2025-03-31Reported-$2.22B(m)(m)$3.24B-68.37%$42.60M$535.50M$2.09B$222.00M$948.10M-$55.00M
2024-12-31Reported$566.4M(m)(m)$3.52B16.11%(m)(m)(m)(m)(m)(m)
2024-09-30Reported$895.6M(m)(m)$3.74B23.96%$77.00M*$826.50M*$2.29B$198.40M$1.00B-$4.30M
2024-06-30Reported$546.4M(m)(m)$3.79B14.43%$58.80M*$379.10M*$2.35B$204.10M$1.04B-$65.40M
2024-03-31Reported$894.9M(m)(m)$3.65B24.49%$49.80M$614.60M$2.16B$199.70M$1.02B$90.70M
2023-12-31Reported$189.9M(m)(m)$3.83B4.96%(m)(m)(m)(m)(m)(m)
2023-09-30Reported$1.13B(m)(m)$3.93B28.75%$95.90M*$835.20M*$2.25B$211.20M$1.05B$70.60M
2023-06-30Reported$1.06B(m)(m)$3.91B27.01%$67.80M*$525.10M*$2.31B$208.30M$1.03B$69.00M
2023-03-31Reported$1.13B(m)(m)$3.72B30.38%$47.80M$971.20M$2.19B$182.90M$958.90M$98.00M
2022-12-31Reported$668.5M(m)(m)$3.87B17.29%(m)(m)(m)(m)(m)(m)
2022-09-30Reported$1.26B(m)(m)$4.07B30.97%$103.90M*$869.00M*$2.33B$174.90M$1.02B$73.20M
2022-06-30Reported$1.27B(m)(m)$4.11B30.96%$83.90M*$802.50M*$2.41B$162.60M$981.10M$75.40M
2022-03-31Reported$1.44B(m)(m)$4.18B34.55%$64.50M$1.14B$2.42B$142.30M$915.30M$128.30M
2021-12-31Reported$672.2M(m)(m)$4.33B15.52%(m)(m)(m)(m)(m)(m)
2021-09-30Reported$1.37B(m)(m)$4.52B30.41%$121.00M*$1.09B*$2.96B$152.10M$1.05B-$111.60M
2021-06-30Reported$1.27B(m)(m)$4.56B27.83%$89.30M*$559.40M*$3.25B$147.70M$1.20B$60.10M
2021-03-31Reported$1.16B(m)(m)$4.4B26.28%$49.50M$848.80M$3.30B$184.10M$1.19B$596.30M
2020-12-31Reported$72M(m)(m)$3.59B2.01%(m)(m)(m)(m)(m)(m)
2020-09-30Reported$783.7M(m)(m)$2.95B26.58%$38.20M*$525.00M*$1.81B$129.80M$658.40M$55.90M
2020-06-30Reported$549.9M(m)(m)$2.7B20.40%$44.50M*$379.50M*$1.71B$156.30M$719.40M-$19.40M
2020-03-31Reported$599.7M(m)(m)$2.59B23.17%$43.40M$291.10M$1.71B$114.20M$605.40M$9.90M

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported$135.2M(m)(m)$14.25B0.95%$378.80M$2.32B$9.29B(m)$3.79B-$150.10M
2024-12-31Reported$2.9B(m)(m)$14.69B19.76%$326.00M$2.30B$9.12B(m)$4.10B$11.00M
2023-12-31Reported$3.51B(m)(m)$15.39B22.79%$377.00M$2.90B$8.99B(m)$4.07B$148.20M
2022-12-31Reported$4.64B(m)(m)$16.22B28.63%$406.00M$3.00B$9.77B(m)$4.18B$734.60M
2021-12-31Reported$4.47B(m)(m)$17.81B25.11%$457.20M$3.02B$12.31B$751.10M$4.53B$604.70M
2020-12-31Reported$2.01B(m)(m)$11.82B16.97%$243.00M$1.23B$8.15B$555.10M$3.34B-$51.30M
2019-12-31Reported$2.73B(m)(m)$11.37B24.05%$213.20M$1.80B$7.60B$639.90M$2.56B$137.60M
2018-12-31Reported$3.02B(m)(m)$11.27B26.76%$252.10M$2.34B$7.43B$704.50M$2.44B-$54.10M

Similar stocks

Stock NameCountryMarket CapPE Ratio
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Royalty Pharma plc (RPRX)United States$22.628B
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17